Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
49
INSM Quote, Financials, Valuation and Earnings
Last price:
$174.10
Seasonality move
:
4.92%
Day range:
$173.24 - $175.25
52-week range:
$60.40 - $212.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
74.06x
P/B ratio:
39.25x
Volume:
1.8M
Avg. volume:
3.6M
1-year change:
152.09%
Market cap:
$37.1B
Revenue:
$363.7M
EPS (TTM):
-$6.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INSM
Insmed, Inc.
|
$174.3M | -$1.36 | 66.86% | -2.57% | $214.78 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.72 | 98.51% | -58.59% | $491.92 |
|
BIIB
Biogen, Inc.
|
$2.2B | $1.75 | -5.28% | -4.28% | $182.07 |
|
CRMD
CorMedix, Inc.
|
$127.5M | $0.70 | 308.6% | 219.78% | $19.00 |
|
NKTR
Nektar Therapeutics
|
$10.4M | -$2.90 | -64.24% | -1474.64% | $114.43 |
|
PFE
Pfizer Inc.
|
$16.9B | $0.56 | -4.67% | 694.29% | $28.62 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INSM
Insmed, Inc.
|
$174.04 | $214.78 | $37.1B | -- | $0.00 | 0% | 74.06x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$397.65 | $491.92 | $52.5B | 1,653.43x | $0.00 | 0% | 16.31x |
|
BIIB
Biogen, Inc.
|
$175.99 | $182.07 | $25.8B | 16.05x | $0.00 | 0% | 2.66x |
|
CRMD
CorMedix, Inc.
|
$11.63 | $19.00 | $916.3M | 5.66x | $0.00 | 0% | 3.92x |
|
NKTR
Nektar Therapeutics
|
$42.28 | $114.43 | $731.5M | -- | $0.00 | 0% | 43.60x |
|
PFE
Pfizer Inc.
|
$24.90 | $28.62 | $141.6B | 14.51x | $0.43 | 6.91% | 2.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INSM
Insmed, Inc.
|
44.07% | 2.489 | 2.43% | 4.18x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.206 | 4.61% | 2.37x |
|
BIIB
Biogen, Inc.
|
26.58% | 0.665 | 32.07% | 1.77x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.954 | 0.48% | 1.60x |
|
NKTR
Nektar Therapeutics
|
66.26% | 7.327 | 16.97% | 4.07x |
|
PFE
Pfizer Inc.
|
39.94% | 0.405 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
BIIB
Biogen, Inc.
|
$1.6B | $613.8M | 6.76% | 9.36% | 25% | $1.2B |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
NKTR
Nektar Therapeutics
|
$11.6M | -$31.5M | -54.14% | -327.67% | -267.45% | -$48.9M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
Insmed, Inc. vs. Competitors
-
Which has Higher Returns INSM or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -259.95% compared to Insmed, Inc.'s net margin of 20.1%. Insmed, Inc.'s return on equity of -193.23% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital INSMInsmed, Inc.78.29% -$1.75 $1.7B ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About INSM or ALNY?
Insmed, Inc. has a consensus price target of $214.78, signalling upside risk potential of 23.5%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 23.71%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Insmed, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INSMInsmed, Inc.17 1 0 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is INSM or ALNY More Risky?
Insmed, Inc. has a beta of 1.085, which suggesting that the stock is 8.523% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.539%.
-
Which is a Better Dividend Stock INSM or ALNY?
Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INSM or ALNY?
Insmed, Inc. quarterly revenues are $142.3M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Insmed, Inc.'s net income of -$370M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,653.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 74.06x versus 16.31x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INSMInsmed, Inc.74.06x -- $142.3M -$370M ALNYAlnylam Pharmaceuticals, Inc.16.31x 1,653.43x $1.2B $251.1M
-
Which has Higher Returns INSM or BIIB?
Biogen, Inc. has a net margin of -259.95% compared to Insmed, Inc.'s net margin of 19%. Insmed, Inc.'s return on equity of -193.23% beat Biogen, Inc.'s return on equity of 9.36%.
Company Gross Margin Earnings Per Share Invested Capital INSMInsmed, Inc.78.29% -$1.75 $1.7B BIIBBiogen, Inc.64.29% $3.17 $24.8B -
What do Analysts Say About INSM or BIIB?
Insmed, Inc. has a consensus price target of $214.78, signalling upside risk potential of 23.5%. On the other hand Biogen, Inc. has an analysts' consensus of $182.07 which suggests that it could grow by 3.45%. Given that Insmed, Inc. has higher upside potential than Biogen, Inc., analysts believe Insmed, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INSMInsmed, Inc.17 1 0 BIIBBiogen, Inc.14 18 1 -
Is INSM or BIIB More Risky?
Insmed, Inc. has a beta of 1.085, which suggesting that the stock is 8.523% more volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.127, suggesting its less volatile than the S&P 500 by 87.301%.
-
Which is a Better Dividend Stock INSM or BIIB?
Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INSM or BIIB?
Insmed, Inc. quarterly revenues are $142.3M, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Insmed, Inc.'s net income of -$370M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 16.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 74.06x versus 2.66x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INSMInsmed, Inc.74.06x -- $142.3M -$370M BIIBBiogen, Inc.2.66x 16.05x $2.5B $466.5M
-
Which has Higher Returns INSM or CRMD?
CorMedix, Inc. has a net margin of -259.95% compared to Insmed, Inc.'s net margin of 49.9%. Insmed, Inc.'s return on equity of -193.23% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital INSMInsmed, Inc.78.29% -$1.75 $1.7B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About INSM or CRMD?
Insmed, Inc. has a consensus price target of $214.78, signalling upside risk potential of 23.5%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 63.37%. Given that CorMedix, Inc. has higher upside potential than Insmed, Inc., analysts believe CorMedix, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INSMInsmed, Inc.17 1 0 CRMDCorMedix, Inc.4 0 0 -
Is INSM or CRMD More Risky?
Insmed, Inc. has a beta of 1.085, which suggesting that the stock is 8.523% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.753%.
-
Which is a Better Dividend Stock INSM or CRMD?
Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INSM or CRMD?
Insmed, Inc. quarterly revenues are $142.3M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Insmed, Inc.'s net income of -$370M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 74.06x versus 3.92x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INSMInsmed, Inc.74.06x -- $142.3M -$370M CRMDCorMedix, Inc.3.92x 5.66x $104.3M $108.6M
-
Which has Higher Returns INSM or NKTR?
Nektar Therapeutics has a net margin of -259.95% compared to Insmed, Inc.'s net margin of -301.29%. Insmed, Inc.'s return on equity of -193.23% beat Nektar Therapeutics's return on equity of -327.67%.
Company Gross Margin Earnings Per Share Invested Capital INSMInsmed, Inc.78.29% -$1.75 $1.7B NKTRNektar Therapeutics98.34% -$1.87 $252.2M -
What do Analysts Say About INSM or NKTR?
Insmed, Inc. has a consensus price target of $214.78, signalling upside risk potential of 23.5%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 170.65%. Given that Nektar Therapeutics has higher upside potential than Insmed, Inc., analysts believe Nektar Therapeutics is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INSMInsmed, Inc.17 1 0 NKTRNektar Therapeutics6 1 0 -
Is INSM or NKTR More Risky?
Insmed, Inc. has a beta of 1.085, which suggesting that the stock is 8.523% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.306, suggesting its more volatile than the S&P 500 by 30.624%.
-
Which is a Better Dividend Stock INSM or NKTR?
Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INSM or NKTR?
Insmed, Inc. quarterly revenues are $142.3M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Insmed, Inc.'s net income of -$370M is lower than Nektar Therapeutics's net income of -$35.5M. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 74.06x versus 43.60x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INSMInsmed, Inc.74.06x -- $142.3M -$370M NKTRNektar Therapeutics43.60x -- $11.8M -$35.5M
-
Which has Higher Returns INSM or PFE?
Pfizer Inc. has a net margin of -259.95% compared to Insmed, Inc.'s net margin of 21.32%. Insmed, Inc.'s return on equity of -193.23% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital INSMInsmed, Inc.78.29% -$1.75 $1.7B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About INSM or PFE?
Insmed, Inc. has a consensus price target of $214.78, signalling upside risk potential of 23.5%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.95%. Given that Insmed, Inc. has higher upside potential than Pfizer Inc., analysts believe Insmed, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings INSMInsmed, Inc.17 1 0 PFEPfizer Inc.7 15 1 -
Is INSM or PFE More Risky?
Insmed, Inc. has a beta of 1.085, which suggesting that the stock is 8.523% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.
-
Which is a Better Dividend Stock INSM or PFE?
Insmed, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Insmed, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios INSM or PFE?
Insmed, Inc. quarterly revenues are $142.3M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Insmed, Inc.'s net income of -$370M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Insmed, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed, Inc. is 74.06x versus 2.26x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INSMInsmed, Inc.74.06x -- $142.3M -$370M PFEPfizer Inc.2.26x 14.51x $16.7B $3.6B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
